13 Biotech Investors in San Francisco — 13 Currently Deploying
Updated
Funds (13)
Invest first in founders making mutants a reality by reimagining the universe. Generalist investors backing companies that make 1 billion lives better through bold bets in deep tec…
Kleiner Perkins partners with visionary founders to build transformative companies that change how the world works. The fund emphasizes team building, network facilitation, and bus…
Accelerating AI-native founders at the earliest stages. Lead early rounds in companies and founders building the future, providing that first check before others think you're onto …
Champion inspired and obsessive builders across seed stage, from enterprise SaaS to sustainability, health, hard tech, AI, infrastructure, consumer, and crypto. Provide guidance fr…
Bold, early, impactful ventures with brutal honesty. Believe in world-class teams making contrarian bets on impossibly big ideas, from AI to cleantech to deep tech.
NFX identifies and backs founders building companies with network effects. The fund emphasizes software development, founder support through content/tools, and emerging technologie…
Experienced founders (particularly serial/exit founders) win 22x more often. Zero-equity retreats attract elite repeat founders who avoid traditional accelerators, enabling first-m…
A fund of 500+ Y Combinator alumni investing in and supporting top startups from Y Combinator, the world's top accelerator.
Investing in deeptech and foundational technologies that remove structural constraints to sustainable scale in food, agriculture, and planetary health, with AI as core infrastructu…
Partner at inception with technically brilliant founders who see past impossible to inevitable. Invest in technical breakthroughs becoming world-changing companies, particularly in…
Correlation Ventures backs groundbreaking technology and data science companies that solve industry problems through rapid decision-making and industry-leading networks.
Deep tech venture capital backing brilliant entrepreneurs addressing the hardest, highest-stakes problems in the world, using AI to unlock potential across sectors.
Partner with entrepreneurs from early days through every stage of growth, focusing on transformative technology across AI/ML, biotech, cloud, consumer, and crypto sectors.
Which of these Biotech funds actually fits your startup?
DryPowder's AI matching ranks all 13 by thesis fit, check size, and deployment status.
Get my fund matches →Related investor lists
Frequently asked questions
How many biotech investors are actively deploying right now?
DryPowder tracks 13 biotech funds. Of these, 13 are currently deploying capital based on recent fund closes, portfolio activity, and partner signals. Use DryPowder's fund matching to see which ones fit your specific startup.
What check size do biotech VCs write?
Among 13 biotech funds on DryPowder, check sizes run from $100K–$50M. Ranges vary by fund size, vintage, and whether the fund leads rounds. Each fund profile shows check size detail and lead preference.
How do I get a meeting with a biotech VC?
A warm intro is still the fastest path. Most biotech VCs on DryPowder do accept cold outreach or direct applications, but response rates vary widely by fund. Before reaching out, use DryPowder's AI matching to get a fit score and specific talking points. Founders who lead with thesis-aligned framing get significantly better response rates than those sending the same deck to every fund on a list.
What do biotech VCs look for beyond a good deck?
Most biotech investors evaluate three things before reading your deck in detail: your background in the space, whether they have seen the problem from multiple portfolio companies, and whether anyone they trust vouches for you. After that, the deck needs to show market size, a clear problem-solution fit specific to biotech, and early evidence of customer demand. Thesis alignment matters more in biotech than in generalist investing because these funds see a high volume of pitches in the same space.
How many biotech investors should I be talking to at once?
Most fundraisers recommend a parallel process: identify 20-40 target investors but approach your highest-fit funds first. Of the 13 biotech funds currently deploying, not all will match your specific stage and sector. Use fund matching to find your top 10-15, approach those first, collect feedback, then go wider. Going to every fund simultaneously without qualifying first burns bridges and dilutes the urgency that helps close a round.
How is DryPowder different from building a VC list on LinkedIn or Crunchbase?
The fund list you build on LinkedIn or Crunchbase is roughly the same list every other founder is building. DryPowder adds three things a manual search cannot: deployment signals (which funds have recently closed new vehicles and are actively writing checks), AI thesis matching (which of the 13 biotech funds actually fits your specific startup, ranked by fit), and verified partner contact details. The goal is 15 targeted, thesis-aligned pitches instead of 150 generic ones.
How DryPowder compares
See all tool comparisons → · best alternatives by platform →